JP2017536114A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536114A5
JP2017536114A5 JP2017524014A JP2017524014A JP2017536114A5 JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5 JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017524014 A JP2017524014 A JP 2017524014A JP 2017536114 A5 JP2017536114 A5 JP 2017536114A5
Authority
JP
Japan
Prior art keywords
vnar
amino acid
encode
domain
codons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017524014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536114A (ja
JP6734271B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/002086 external-priority patent/WO2016070959A1/en
Publication of JP2017536114A publication Critical patent/JP2017536114A/ja
Publication of JP2017536114A5 publication Critical patent/JP2017536114A5/ja
Application granted granted Critical
Publication of JP6734271B2 publication Critical patent/JP6734271B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017524014A 2014-11-03 2015-10-21 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用 Expired - Fee Related JP6734271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14003700 2014-11-03
EP14003700.3 2014-11-03
PCT/EP2015/002086 WO2016070959A1 (en) 2014-11-03 2015-10-21 Methods for generating bispecific shark variable antibody domains and use thereof

Publications (3)

Publication Number Publication Date
JP2017536114A JP2017536114A (ja) 2017-12-07
JP2017536114A5 true JP2017536114A5 (cg-RX-API-DMAC7.html) 2018-11-29
JP6734271B2 JP6734271B2 (ja) 2020-08-05

Family

ID=51945671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017524014A Expired - Fee Related JP6734271B2 (ja) 2014-11-03 2015-10-21 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用

Country Status (8)

Country Link
US (1) US11001640B2 (cg-RX-API-DMAC7.html)
EP (1) EP3215531A1 (cg-RX-API-DMAC7.html)
JP (1) JP6734271B2 (cg-RX-API-DMAC7.html)
CN (1) CN107074961A (cg-RX-API-DMAC7.html)
AU (1) AU2015342264B2 (cg-RX-API-DMAC7.html)
CA (1) CA2966397A1 (cg-RX-API-DMAC7.html)
IL (1) IL252008A0 (cg-RX-API-DMAC7.html)
WO (1) WO2016070959A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11097010B2 (en) * 2016-08-06 2021-08-24 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN112940120B (zh) * 2021-05-14 2021-08-17 深圳海创生物技术有限公司 降钙素原单域抗体及其应用和试剂盒
CN118475603A (zh) * 2021-11-03 2024-08-09 香港城市大学深圳研究院 高亲和力抗EGFP和抗SARS-CoV-2 vNAR单域抗体及其用途
CN115975010A (zh) * 2022-08-31 2023-04-18 闽江学院 一种十足目虹彩病毒1的单域抗体及其制备方法和应用
CN116143913A (zh) * 2022-12-30 2023-05-23 闽江学院 一种结合SARS-CoV-2 RBD的鲨鱼源单域抗体及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010687A (es) 2001-05-24 2004-07-01 Zymogentetics Inc Proteinas de fusion de taci-inmunoglobulina.
PE20130527A1 (es) * 2010-03-03 2013-05-09 Boehringer Ingelheim Int Polipeptidos de union a a-beta biparatopicos
PL2606064T3 (pl) * 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
EP2847229B1 (en) * 2012-05-07 2022-09-07 Elasmogen Limited Single domain binding molecule
KR20160010466A (ko) * 2013-04-23 2016-01-27 더 유니버시티 코트 오브 더 유니버시티 오브 애버딘 Icosl에 대한 치료학적 표적 특이적 vnar 도메인의 단리

Similar Documents

Publication Publication Date Title
JP2017536114A5 (cg-RX-API-DMAC7.html)
JP2017114866A5 (cg-RX-API-DMAC7.html)
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
JP2016029056A5 (cg-RX-API-DMAC7.html)
IL275270A (en) Recombinant cell surface capture proteins
JP2016026303A5 (cg-RX-API-DMAC7.html)
HRP20250850T1 (hr) Antitijela protiv claudina 18.2 korisna u dijagnozi raka
AR108066A1 (es) Receptores quiméricos para cll-1 y métodos de uso de los mismos
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
JP2019500862A5 (cg-RX-API-DMAC7.html)
IL273196B1 (en) Claudin 6 antibodies and methods of cancer treatment
RU2018137419A (ru) Связывающиеся с cd38 и pd-l1 молекулы
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2015529826A5 (cg-RX-API-DMAC7.html)
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
JP2013535191A5 (cg-RX-API-DMAC7.html)
FI3227342T4 (fi) Proteiininen heterodimeeri ja sen käyttö
JP2014158485A5 (cg-RX-API-DMAC7.html)
JP2016536322A5 (cg-RX-API-DMAC7.html)
JP2016502843A5 (cg-RX-API-DMAC7.html)
JP7628153B2 (ja) mRNAディスプレイ抗体ライブラリー及び方法
JP2018528786A5 (cg-RX-API-DMAC7.html)
JP2017538412A5 (cg-RX-API-DMAC7.html)
JP2013507970A5 (cg-RX-API-DMAC7.html)
JP2017522886A5 (cg-RX-API-DMAC7.html)